Cardiac-resynchronization therapy for mild-to-moderate heart failure

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Cardiac-resynchronization therapy (CRT) is beneficial for patients with left ventricular systolic dysfunction and wide QRS complexes.
• Many patients eligible for CRT are also candidates for implantable cardioverter-defibrillators (ICDs).
• The study investigates the added benefit of CRT to ICDs in reducing mortality and morbidity.

Purpose of the Study:

• To evaluate the efficacy of combining CRT with ICD and optimal medical therapy.
• To determine the impact on mortality and heart failure hospitalizations.
• To assess the safety profile of combined ICD and CRT therapy.

Main Methods:

• Randomized assignment of patients with NYHA class II-III heart failure, LVEF ≤30%, and wide QRS (≥120ms intrinsic or ≥200ms paced) to ICD alone or ICD + CRT.
• Primary outcome: all-cause death or heart failure hospitalization.
• Follow-up duration: mean of 40 months for 1798 patients.

Main Results:

• The ICD + CRT group showed a significant reduction in the primary outcome (33.2% vs. 40.3%, HR 0.75, P<0.001).
• Mortality was lower in the ICD + CRT group (HR 0.75, P=0.003).
• Heart failure hospitalizations were reduced (HR 0.68, P<0.001), but adverse events were higher (124 vs. 58, P<0.001).

Conclusions:

• Combining CRT with ICD therapy significantly reduces death and heart failure hospitalizations in selected NYHA class II-III heart failure patients.
• The benefits of ICD + CRT are accompanied by an increased rate of adverse events in the short term post-implantation.
• This strategy offers a valuable treatment option for heart failure patients with specific electrical conduction abnormalities.